Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial

NEXT STORY
Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market
PREV STORY
Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline

author_avatar
NASDAQ Market News

Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)

- DGT Designed to identify patient specific foods, that when removed, may alleviate an ...

author_avatar
NASDAQ Market News

HOOKIPA Pharma To Report First Quarter 2020 Financial Results on May 14, 2020

author_avatar
NASDAQ Market News